Can Ozempic Make You Climb Harder?

No study has ever tested a weight-loss drug on climbers, so there’s no proven answer — but the trade-off is sharp. Climbing is about strength-to-weight, so dropping fat on a shot like Ozempic or Zepbound can lift your ratio and make steep moves feel lighter. The catch: a big share of the weight you lose is muscle — and grip, forearms, and back are exactly what climbing runs on — while an appetite-killing drug in a sport that already struggles with under-eating carries a real risk (a low-energy state called RED-S). Of the sports we’ve looked at, this is the one where the downsides bite hardest.

Here’s the full case each way — what helps, what hurts, and what climbers report ↓

What are these drugs?

Semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are once-a-week injections. The short version:

  • They quiet your appetite and slow your stomach, so you eat less.
  • The weight comes off — often around 15% of your body weight, sometimes more[1][2].
  • They were built for weight loss and diabetes. Nobody built them for climbing.

Why it might make you a better climber

The case for is real physics, and it’s the reason climbers care at all.

Better strength-to-weight.

  • Climbing grade is largely a ratio: how strong you are versus how much you weigh.
  • Drop fat and keep your strength, and that ratio improves — moves feel lighter, especially on steep, overhanging terrain where you’re fighting your own weight.
  • This is the real pro here, and for a climber carrying extra weight it can be a big one.

Less to haul, less to hurt.

  • Less bodyweight is less load through your fingers, shoulders, and toes on every move.
  • For someone heavier who’s just getting into climbing, reaching a healthy weight can make the whole thing more doable.

(One pro that shows up for other sports doesn’t really apply here: climbing isn’t a walk-for-hours game, so the “you can go longer” benefit these drugs show in walking tests doesn’t map cleanly onto a bouldering session.)

Why it might make you worse

Here’s where climbing is different from golf or pickleball — the downsides hit the exact things climbing depends on.

You lose muscle, and climbing is muscle.

  • When people drop weight on these drugs, studies have shown a large chunk of it — somewhere between a quarter and 40% — is muscle (lean mass), not fat.
  • Climbing runs on fingers, forearms, back, and core. Losing muscle off your forearms and grip is a direct hit to the one thing you literally hang from.
  • Lighter and weaker can easily be a wash — or worse — for a trained climber.

The under-eating problem is bigger in climbing than anywhere.

  • Climbing already has a well-known problem with athletes under-eating to chase a lower weight, tipped into a low-energy state doctors call RED-S (relative energy deficiency in sport).
  • RED-S is tied to stress fractures, weaker bones, hormone disruption, worse recovery, and worse climbing — not better.
  • A drug whose whole job is to switch off appetite, dropped into a culture that already flirts with under-eating, is the single biggest reason to be careful here — and it’s the risk the sport’s own coaches and physios raise loudest.

The everyday stuff, too.

  • Gut trouble (the GI side effects) — nausea and bloating are the most common complaints.[3]
  • No fuel in the tank for a long session or a multi-pitch day, and it’s easy to under-drink when you’re not hungry.
  • Under-fueled tendons and bones recover worse — rough for a sport that’s already hard on fingers.

How it all adds up

In climbing the good and the bad don’t just coexist — they can turn into a spiral:

  • Lighter helps the grade; weaker fingers hurt it. The muscle you lose is the muscle that pulls the moves. For a trained climber, that can cancel the weight benefit outright.
  • The RED-S spiral. Chase weight → eat too little → lose muscle, bone, and hormones → get injured (stress fractures, pulley tears that heal slowly) → climb worse. A drug that kills appetite can pour fuel on a spiral the sport already fights.
  • The one way it clearly works. If a heavier climber loses fat while keeping muscle — strength training plus enough protein — strength-to-weight genuinely improves. But that’s the opposite of how these drugs tend to go without deliberate effort, which is the whole tension.

What climbers say

There’s no set of climbing-specific stories yet, so here’s the nearest thing — athletes across sports, talking online.

What some report after losing weight (just their words)

  • Moves felt lighter
  • Sends came easier
  • Less joint ache

What others report (just their words)

  • Lost grip and forearm strength
  • No energy for a full session
  • Couldn’t eat enough to train
  • Felt weak on the wall

The loudest pattern: it depends where you start.

  • People who were heavy and out of shape say they can finally move.
  • Fitter, stronger climbers say they lost the thing they’d built.
  • A climber lands somewhere between, depending on how much fat there is to lose and how much of their climbing is pure strength.

Is anyone at the crag actually doing this?

Not on the record.

  • No named climber has said they use a weight-loss drug to climb harder.
  • Climbing’s weight culture makes it a live topic in forums, but real performance claims are absent.
  • The sport’s history with disordered eating hangs over any of that chatter.

Thinking about it?

A few things worth knowing:

  • The muscle-loss and under-eating (RED-S) risks are what make this a bigger deal in climbing than in most sports.
  • Climbing’s history with disordered eating is the reason an appetite-suppressing drug raises more flags here than elsewhere.
  • The cheap, self-mixed versions people buy online have sent folks to the hospital after they measured it wrong.[4] A prescription from a real pharmacy is a different thing from a mystery vial.

The catch

There is no climbing study. None.

  • No researcher has handed these drugs to climbers and measured their grades, their grip, or their injuries.
  • The people in the studies we do have were middle-aged, heavy, and out of shape — not climbers.
  • So everything above — the case for and the case against — is pulled from what these drugs do in other people, not measured in climbers.

The bottom line

It comes down to one trade nobody’s tested on a climber: dropping fat can lift your strength-to-weight and help you climb harder, but these drugs take muscle along with the fat, and climbing runs on muscle. Layer on a sport that already has a dangerous relationship with eating, and the under-fueling risk isn’t a footnote — in climbing it’s the biggest part of the trade.

Frequently asked questions

Does losing weight make you climb harder?
Climbing grade is largely strength for your weight, so dropping fat can help. But these drugs also cut muscle, and climbing runs on muscle — and chasing weight is how a lot of climbers get hurt. No one has tested a GLP-1 on climbers.
Can a weight-loss drug hurt your grip strength?
It might. A big share of the weight lost on these drugs is muscle (lean mass), and grip and finger strength are muscle. No study has measured a climber’s strength before and after, so it’s a worry, not a proven fact.
Isn't climbing a sport where losing weight always helps?
Not that simple. The weight that helps you is fat; the muscle that comes off with it is the engine. And under-eating to chase a grade has a serious, well-documented downside in climbing (a low-energy state called RED-S).
Is it safe for climbers?
The under-eating and low-energy (RED-S) risk in climbing is real, and an appetite-suppressing drug dropped into that culture is a serious concern — the biggest reason climbers weigh this one carefully. No one has studied a GLP-1 in climbers.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183.
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024. DOI: 10.1056/NEJMoa2206038.
  3. (FAERS disproportionality analysis) Metabolic and nutritional adverse events of GLP-1 receptor agonists: a FAERS pharmacovigilance study (semaglutide reporting odds ratio 3.34) Front Pharmacol. 2024. Source.
  4. U.S. Food and Drug Administration FDA alert: dosing errors with compounded injectable semaglutide led to 5–10x overdoses, some requiring hospitalization FDA safety communication, July 2024. 2024. Source.